Ibuprofen Kabi (Ibuprofen)

Ibuprofen in this product works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins. Lower prostaglandin levels reduce inflammation, diminish pain signaling, and lower body temperature, delivering the therapeutic effects observed with the intravenous route.

The specific dose and infusion rate of Ibuprofen Kabi are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and therapeutic goals. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

Safety data for intravenous ibuprofen in pregnancy are limited, and the product is generally classified as contraindicated or used only when the potential benefit justifies the risk. It is excreted in breast milk, so breastfeeding mothers should consult their physician before use.

To request Ibuprofen Kabi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Compared with other intravenous NSAIDs, ibuprofen offers a well‑characterized safety profile and effective analgesia at doses that are often lower than those of ketorolac. Unlike opioid analgesics, it does not cause respiratory depression, but it shares class‑related risks such as gastrointestinal bleeding and renal effects.

Ibuprofen Kabi must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken. Before administration, allow the product to reach room temperature if required by the infusion protocol, and inspect for particulate matter or discoloration.

The medication is given by intravenous infusion. The prescriber determines the infusion volume and rate, typically over 15‑30 minutes, depending on the clinical situation. Administration should be performed by qualified healthcare personnel using aseptic technique and appropriate IV equipment.

Serious risks include gastrointestinal bleeding, acute renal injury, severe hypersensitivity reactions such as anaphylaxis, and hepatic dysfunction. Patients with a history of ulcer disease, renal impairment, cardiovascular disease, or known NSAID allergy require careful assessment before receiving the drug.

Ibuprofen Kabi is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration, severe renal or hepatic failure, and in the third trimester of pregnancy. Caution is also advised for individuals on anticoagulants, certain antihypertensives, or those with uncontrolled hypertension.